Temozolomide promotes genomic and phenotypic changes in glioblastoma cells
Temozolomide promotes genomic and phenotypic changes in glioblastoma cells
About this item
Full title
Author / Creator
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Temozolomide (TMZ) is a first-line drug for the treatment of glioblastoma. Long-term TMZ-treated tumour cells acquire TMZ resistance by profound reprogramming of the transcriptome, proteome, kinome, metabolism, and demonstrate versatile and opposite changes in proliferation, invasion, in vivo growth, and drug cross-resistance. We hypothesized that...
Alternative Titles
Full title
Temozolomide promotes genomic and phenotypic changes in glioblastoma cells
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4858898
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4858898
Other Identifiers
ISSN
1475-2867
E-ISSN
1475-2867
DOI
10.1186/s12935-016-0311-8
